Moderate

Anaemia of chronic kidney disease (renal anaemia)

renal anaemia · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Normochromic normocytic anaemia from reduced erythropoietin production and functional iron deficiency in CKD. Management requires iron repletion before and alongside erythropoiesis-stimulating agents (ESAs) or HIF-PH inhibitors, targeting haemoglobin 100-120 g/L (not normal).

Red flags

  • Hb falling rapidly or symptomatic anaemia with chest pain/dyspnoea
  • Evidence of active GI bleeding
  • ESA hyporesponsiveness despite iron repletion
  • Pure red cell aplasia (anti-EPO antibodies) — sudden transfusion dependence
  • Thrombotic event on ESA with over-target Hb

Assessment

Differential diagnosis

  • Erythropoietin deficiency of CKD
  • Absolute/functional iron deficiency
  • Blood loss (GI, dialysis circuit)
  • B12/folate deficiency
  • Haemolysis or marrow suppression
  • Underlying haematological malignancy / myeloma

Investigations

  • FBC with indices and reticulocytes
  • Ferritin and transferrin saturation (TSAT)
  • B12, folate
  • CRP (inflammation causes functional iron deficiency)
  • Renal function and CKD stage
  • Haematinics plus blood film / myeloma screen if atypical (e.g. very low or disproportionate anaemia)

Management

  • Confirm anaemia attributable to CKD and exclude other causes (iron, B12, folate, blood loss, haemolysis, malignancy)
  • Check iron status: aim TSAT >20% and ferritin >100 micrograms/L (non-dialysis) / >200 micrograms/L (haemodialysis)
  • Replete iron first: oral iron trial in non-dialysis CKD, IV iron if oral ineffective/not tolerated or in haemodialysis
  • Only start an ESA once iron replete and reversible causes addressed
  • Set individualised Hb target 100-120 g/L; do not aim for normal Hb (higher targets increase stroke/thrombosis)
  • Start ESA (epoetin or darbepoetin) at low dose and titrate by Hb response (rate of rise <20 g/L per 4 weeks)
  • Consider an oral HIF-prolyl hydroxylase inhibitor (e.g. roxadustat/daprodustat) as an alternative where available
  • Monitor Hb every 2-4 weeks during titration, then monthly when stable
  • Control blood pressure before/while on ESA; hold or reduce ESA if BP rises or Hb >120 g/L
  • Investigate ESA hyporesponsiveness (iron, inflammation, blood loss, hyperparathyroidism, malignancy)
  • Minimise blood loss and transfusion to preserve transplant candidacy
  • Reassess iron indices every 1-3 months on treatment

Drugs & doses

Ferrous sulfate 200 mg PO once daily or alternate days (oral trial)
Ferric carboxymaltose IV 500-1000 mg per dose (max 20 mg/kg) as per local protocol
Iron sucrose IV 200 mg per session (common in haemodialysis)
Darbepoetin alfa 0.45 micrograms/kg SC once weekly or 0.75 micrograms/kg every 2 weeks, titrated
Epoetin alfa/beta 50 units/kg SC three times weekly, titrated to Hb
Roxadustat 70-100 mg PO three times weekly (where licensed), titrated

Disposition

Outpatient CKD/renal anaemia clinic. Admit for symptomatic severe anaemia or active bleeding. Haematology referral for suspected pure red cell aplasia or unexplained hyporesponsiveness.

Complications & pitfalls

  • Hypertension and stroke/thrombosis from over-correction
  • ESA resistance
  • Iron overload from excessive IV iron
  • Anaphylactoid reactions to IV iron
  • Pure red cell aplasia (rare)
  • Transfusion sensitisation reducing transplant options

Exam pearls

  • Replete iron before escalating ESA dose
  • Target Hb 100-120 g/L, never normal — higher targets cause harm
  • Functional iron deficiency: low TSAT with normal/high ferritin from inflammation
  • Investigate blood loss if ESA requirements rise
  • Avoid transfusion where possible in transplant candidates

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.